A highly selective inhibitor of discoidin domain receptor‐1 (DDR1‐IN‐1) protects corneal epithelial cells from YAP/ACSL4‐mediated ferroptosis in dry eye

Abstract

Background and PurposeThis study investigated the involvement of discoidin domain receptor (DDR) in dry eye and assessed the potential of specific DDR inhibitors as a therapeutic strategy for dry eye by exploring the underlying mechanism.Experimental ApproachDry eye was induced in Wistar rats by applying 0.2% benzalkonium chloride (BAC), after which rats were treated topically for 7 days with DDR1‐IN‐1, a selective inhibitor of DDR1. Clinical manifestations of dry eye were assessed on Day‐7 post‐treatment. Histological evaluation of corneal damage was performed using haematoxylin and eosin (H&E) staining. In vitro, immortalized human corneal epithelial cells (HCECs) exposed to hyperosmotic stress (HS) were treated with varying doses of DDR1‐IN‐1 for 24 h. The levels of lipid peroxidation in dry eye corneas or HS‐stimulated HCECs were assessed. Protein levels of DDR1/DDR2 and related pathways were detected by western blotting. The cellular distribution of acyl‐CoA synthetase long chain family member 4 (ACSL4) and Yes‐associated protein (YAP) was evaluated using immunohistochemistry or immunofluorescent staining.Key ResultsIn dry eye corneas, only DDR1 expression was significantly up‐regulated compared with normal controls. DDR1‐IN‐1 treatment significantly alleviated dry eye symptoms in vivo. The treatment remarkably reduced lipid hydroperoxide (LPO) levels and suppressed the expression of ferroptosis markers, particularly ACSL4. Overexpression or reactivation of YAP diminished the protective effects of DDR1‐IN‐1, indicating the involvement of the Hippo/YAP pathway in DDR1‐targeted therapeutic effects.Conclusions and ImplicationsThis study confirms the significance of DDR1 in dry eye and highlights the potential of selective DDR1 inhibitor(s) for dry eye treatment.